Lau, Yu-LungYu-LungLauFan Leung, TingTingFan LeungSirvan Cetin, BenhurBenhurSirvan CetinCagri Dinleyici, EnerEnerCagri DinleyiciLI-MIN HUANGHalperin, Scott AScott AHalperinHsiao, Chien-ChouChien-ChouHsiaoTapiero, BruceBruceTapieroTipton, MaryMaryTiptonCampbell, James DJames DCampbellMoerman, LeentjeLeentjeMoermanPovey, MichaelMichaelPoveyBi, DanDanBiSingh, TinaTinaSingh2023-01-182023-01-182022-03-250264-410Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/627429The introduction of rotavirus vaccines in national immunization programs has decreased mortality and hospitalizations due to diarrhea. GSK's live-attenuated, human rotavirus vaccine (HRV) is a 2-dose vaccine for oral administration. Following the detection of porcine circovirus type 1 (PCV-1) in HRV, a PCV-free (no detection of PCV-1 and PCV-2 according to the detection limits of tests used) HRV was developed. The immunogenicity, reactogenicity and safety of a liquid (liq) PCV-free HRV were assessed in two prior studies. The present study aimed to generate additional reactogenicity and safety data.enHuman rotavirus vaccine; Infant; Liquid; Porcine circovirus-free; Reactogenicity; Safety[SDGs]SDG3journal article10.1016/j.vaccine.2022.02.065352325962-s2.0-85125292150WOS:000822935500009https://api.elsevier.com/content/abstract/scopus_id/85125292150